Search fresh public links, source activity, and post angles for Aquestive Therapeutics.
Fresh curated links around Aquestive Therapeutics are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
AQUESTIVE (AQST) Anonymous (not verified) Sun, 04/12/2026 - 05:04 field_thread_url https://cafepharma.com/boards/threads/aquestive-aqst.646620/...
Warren-based pharmaceutical company Aquestive Therapeutics, Inc. has refinanced its existing debt facility with a new $150 million debt facility, with funds managed by Oaktree Capi...
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing...
MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patient...
Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics for their psychedelic treatments. A third recipient in this batch is...
Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axso...
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune...
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the drugmaker to advance a Tourette syndrome candidate that is on the cusp of...
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
Image source: The Motley Fool. DATETuesday, May 12, 2026 at 8:30 a.m. ETCall participantsChief Executive Officer — Andrew Goldberg, M.D.Need a quote from a Motley Fool analyst? Em...
Image source: The Motley Fool. DATETuesday, May 12, 2026 at 8:30 a.m. ETCall participantsChief Executive Officer — Andrew Goldberg, M.D.Need a quote from a Motley Fool analyst? Em...
Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.
Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
The company is acquiring Soleno Therapeutics to add a newly approved Prader‑Willi syndrome treatment to its portfolio.
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an Ast...
This case was filed in 2018 when Alvogen submitted to the FDA an ANDA for approval to market generic Belbuca, a buprenorphine buccal film used to administer the drug transmucosally...
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.